Please assess the completion status of the following clinical trial:

Trial Title: BOTOX® for the Treatment of Platysma Prominence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period~* A female participant is eligible to participate if she is not pregnant (has a negative urine pregnancy result prior to randomization), not breastfeeding, and at least one of the following conditions applies:~  1. Not a woman of childbearing potential (WOCBP) OR~ 2. A WOCBP who agrees to follow the studies contraceptive guidance during the treatment and follow-up period through study exit.~* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this study's protocol~Exclusion Criteria:~* Any medical condition that may put the participant at increased medical risk with exposure to BOTOX®, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function~* Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)~* Anticipated need for surgery or overnight hospitalization during the study~* Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study~* Females who are pregnant, nursing, or planning a pregnancy during the study~* Known immunization or hypersensitivity to any botulinum toxin serotype~* History of alcohol or drug abuse within 12 months of the study~* Participant has tattoos, jewelry, or clothing that cannot be removed, and that obscure the neck

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo as superficial intramuscular injections administered to the platysma muscle on Day 1.
- BOTOX® Low Dose (Type: EXPERIMENTAL): Participants received BOTOX® Low Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.
- BOTOX® High Dose (Type: ACTIVE_COMPARATOR): Participants received BOTOX® High Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).